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ACE inhibition is effective and renoprotective in hypertensive increase in hypertensive ESRD [2]. The optimal strategy
nephrosclerosis: The African American Study of Kidney Dis- to retard this progressive increase remains to be precisely
ease and Hypertension (AASK) trial. An interim analysis of the determined. Promising among the recent interventionsAASK trial at three years demonstrates a renoprotective effect
that have been implicated in slowing the progression of[slower decline in glomerular filtration rate (GFR), delayed
renal disease and prevention of ESRD are arterial bloodonset of significant decrease in GFR, end-stage renal disease
(ESRD) or death, and a decrease in urinary protein excretion] pressure reduction and the use of angiotensin converting
of the angiotensin converting enzyme (ACE) inhibitor, rami- enzyme inhibitors (ACEIs). Unfortunately, no definitive
pril, as compared to the dihydropyridine calcium channel blocker
data are available on the efficacy of this class of antihy-(DHP-CCB), amlodipine, in patients with mild-to-moderate re-
pertensive agents and/or levels of blood pressure controlnal insufficiency. The beneficial effect occurred in the presence
of similar levels of blood pressure control and was apparent for African Americans with progressive renal disease
in patients with proteinuric (beyond the threshold of “dipstick primarily due to low enrollment in randomized con-
positive” proteinuria, 300 mg/day) and non-proteinuric hyper- trolled trials.tensive nephrosclerosis. At the time of the interim analysis,
the effectiveness of the beta-blocker metoprolol was not sig-
nificantly different from that of the ACE inhibitor. The data STUDY DESIGN
suggest that DHP-CCBs should be used with caution in the
The AASK trial is a multicenter, randomized, doublepresence of mild-to-moderate renal insufficiency.
blind, prospective clinical trial sponsored by the National
Institute of Diabetes & Digestive & Kidney Diseases
Mortality from cerebrovascular and coronary artery (NIDDK) of the National Institutes of Health (NIH).
disease caused by hypertension has declined substantially This trial is a 2  3 factorial design involving 21 Clinical
during the last two decades in the USA due, in great part, Centers in the United States, a Central Data Coordinat-
to blood pressure control [1]. During the same period the ing Center, and a Data and Safety Monitoring Board;
prevalence of end-stage renal disease (ESRD) due to hy- 1094 African Americans with hypertensive kidney dis-
pertension has increased progressively. African Ameri- ease of mild-to-moderate severity, defined as glomerular
cans have a greater prevalence and more severe hyper- filtration rates (GFR) between 20 and 65 mL/min/1.73
tension and more significant target organ damage than m2, were enrolled and randomized between February
other racial/ethnic groups in the US. Despite the obser- 1995 and September 1998. The blinded observation pe-
vation that diabetes mellitus is the leading cause of ESRD riod was completed at the end of September 2001.
in the US, among African Americans, hypertension has AASK was designed to evaluate the efficacy of two
been the leading reported cause of ESRD until the year different levels of blood pressure control (low vs. usual)
1995. The United States Renal Data System (USRDS) and one of three antihypertensive agents: a beta blocker
reports that African Americans have a 4.5-fold greater metoprolol (50 to 200 mg/day), Toprolol XL, versus an
likelihood of developing ESRD than Caucasians, with ACEI ramipril (2.5 to 10 mg/day), Altase, versus a
hypertension as a major contributor. The risk of ESRD DHP-CCB amlodipine (5 to 10 mg/day), Norvasc. The
secondary to hypertension in African Americans has blood pressure treatment goals included mean arterial
been reported to be as high as 20-fold greater than in blood pressure (MAP) of 92 mm Hg (125/75) for the
Caucasians. Between 1990 and 1999, there was a 50% “Low” group, or 102 to 107 mm Hg (140/90) for the
“Usual” group. Patients were randomly assigned to am-
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as needed to achieve goal blood pressure. If maximum participants included a mean age 54 years, 61% men,
tolerated doses of the blinded drug failed to reach the mean blood pressure (BP) 151/96 mm Hg, and mean
assigned blood pressure goal, furosemide, a diuretic, and GFR of 46 mm/min/1.73 m2. The median urinary protein/
other agents (doxazosin, clonidine, and hydralazine or creatinine ratio was 0.11, and this ratio exceeded 0.22
minoxidil) were added sequentially to the randomized (corresponding to urine protein excretion of about 300
agent. Individuals with diabetes, other (non-hyperten- mg/day) in approximately one-third of the patients. At
sive) renal diseases, and those with more than 2.5 grams entry to baseline, 62% were taking a calcium channel
of urinary protein excretion/24 hours at baseline were blocker (CCB), 40% an ACEI and 27% a beta-blocker.
specifically excluded. At the time of the interim analysis median follow-up of
The primary endpoints of this study included the rate GFR was approximately 37 months. After three months,
of decline of GFR as determined by iothalamate clear- an average of 57% of patients in both groups received
ance (both chronic, 3 months after the start of therapy, the highest dose of their randomized study drug, approxi-
and total GFR change over the entire follow-up period). mately 75% of patients were on a diuretic, and in both
The main secondary endpoint was a composite including groups, patients took a mean of 1.75 antihypertensive
the time from randomization to (1) a 50% decline in GFR, drugs in addition to their randomized drug.
or an absolute decline of 25 mL/min/1.73 m2, (2) ESRD,
After the three month visit, mean blood pressure val-
or (3) death. Proteinuria (urinary protein-to-creatinine
ues did not differ significantly between the ramipril andratio) was another important secondary endpoint.
amlodipine groups (mean BP  134.5/82.2 mm Hg and
132.9/81.4 mm Hg, respectively). However, among theTREATMENT DECISION
1/3 of patients with baseline urinary protein to creatinine
The decision for an early halt of the amlodipine arm ratio 0.22, the mean rate of GFR decline was 40%
was announced at the 33rd Annual Meeting of the Ameri- slower in the ramipril than the amlodipine group after
can Society of Nephrology (Toronto, Canada, October
three months (chronic phase), and was 36% slower in
13-16, 2000), when the results of an interim analysis of
the ramipril than the amlodipine group from baseline tothe comparison of the amlodipine to ramipril arms were
three years (total slope). Consistent with a strong inversepresented.
association between GFR and proteinuria at baseline,In September 2000, the NIDDK called an early halt
similar results were obtained in the subgroup with base-to the amlodipine arm of the AASK trial after careful
line GFR 40 mL/min/1.73 m2.deliberation by an independent data and safety monitor-
Due to an acute increase in GFR in the amlodipineing board (DSMB). It was observed that patients with
group of patients without frank proteinuria (urinary pro-proteinuria greater than one gram per day demonstrated
tein 300 mg/day), the mean total GFR change fromrenoprotection with the use of either ramipril, the ACEI,
baseline to three years did not differ significantly be-or metoprolol, the beta blocker, as compared to amlodi-
tween the ramipril and amlodipine groups even thoughpine, the DHP-CCB. Analysis of data in patients with
the ramipril group had a 38% slower mean GFR declinebaseline proteinuria above 1 g/day was not included in the
after three months (chronic phase). Additional observa-original primary or secondary endpoint analysis plans.
However, after the onset of the study, results of several tions were that the risk of the clinical composite outcome,
clinical trials and meta analyses revealed the renoprotec- including large declines in GFR, ESRD, or death, was
tive effects of ACEI on proteinuric diabetic and non- reduced by 38% for the entire group (Fig. 1). Moreover,
diabetic renal disease with greater than a gram of pro- the relative risk for ESRD or death was reduced by 41%
teinuria [3]. Moreover, at the initiation of the study, with ramipril, while GFR or death was reduced by 38%
there were no data concerning any differences between (Fig. 1). Of particular interest is the fact that the amlodi-
DHP-CCB and non-DHP-CCB on their effect on renal pine group experienced a significant increase in urinary
function, that is, proteinuria and changes in GFR, in protein excretion compared to the ramipril group irre-
patients with non-diabetic renal disease. spective of the urine protein/creatinine ratio. In the en-
The AASK interim analysis of the amlodipine-rami- tire cohort, the geometric mean urine protein/creatinine
pril comparison was published in the Journal of the Ameri- ratio increased by 58% in the amlodipine group and
can Medical Association on June 6, 2001 [4] and the decreased by 20% in the ramipril group from baseline
complete report was recently published [5]. to six months. From baseline to 36 months the mean
changes were an increase of 8.7% for ramipril and 108%
OBSERVATIONS for amlodipine (Fig. 2).
At the time of the interim analysis, the effectivenessRandomization resulted in baseline demographics that
of the beta-blocker, metoprolol, in risk reduction waswere not significantly different between the amlodipine
and ramipril groups. The baseline characteristics of the not significantly different from that of the ACE inhibitor.
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Fig. 2. Change in glomerular filtration rate in the ramipril ( ) and
amlodipine () groups from baseline at six and 36 months. Reprinted
with permission. Advances in Cardiology. Eugene Raunwald (ed).
McGraw-Hill, 2003.
Fig. 1. Relative risk reduction for patients randomized to ramipril (N
436) as compared to those assigned to amlodipine (N  217). Abbre-
viations are: GFR, glomerular filtration rate; ESRD, end-stage renal hibitor to lower urinary protein excretion has been sug-
disease. Reprinted with permission. Advances in Cardiology. Eugene
gested as an additional mechanism that retards renalRaunwald (ed). McGraw-Hill, 2003.
disease progression. Microalbuminuria and frank pro-
teinuria are risk factors for cardiovascular as well as
renal disease. Prior observations suggesting that ACEIsDISCUSSION
are not effective in African Americans were based on theThis interim analysis clearly demonstrates a renopro-
use of this class of drugs as mono-therapy for blood pres-tective effect of ramipril as compared to amlodipine in
sure control [6]. However, as the results of the AASKhypertensive nephrosclerosis in participants beyond the
demonstrate, when an ACEI is used in combination withthreshold of clinically significant “dipstick positive” pro-
a diuretic and other agents, BP control is achieved andteinuria (300 mg/day or UP/creatinine ratio of greater
the renoprotection is apparent. Moreover, in the AASK
than 0.22). Observations supporting this conclusion in-
study the number of drugs, the percent of participants
clude a significant reduction in risk of the clinical com- on diuretics, and the achieved blood pressure (133/82
posite outcome, a slower decline in GFR, and a reduction mm Hg) were similar for participants randomized to am-
in urinary protein excretion with ramipril as compared lodipine and ramipril. Thus, this strengthens the argu-
to amlodipine. Moreover, a renoprotective effect of ram- ment that the renoprotective effect of ramipril as com-
ipril is suggested in the non-proteinuric participants be- pared to amlodipine is independent of the achieved
cause of a reduction in time to event for the entire group, blood pressures.
and a reduction in urinary protein excretion. This latter
Reprint requests to Janice G. Douglas, Department of Medicine,group also experienced a slowed progression to clinically
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a beneficial effect of ACE inhibition in both diabetic and
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